ImmVue Therapeutics focuses on leveraging allosteric chemistry to enhance immunotherapy, aiming to revitalize patients' immune systems through innovative medicines. The company's approach centers on tunable lymphocyte activation, which is designed to restore immune function and enable the eradication of diseased cells. By targeting novel mechanisms within the immune response, ImmVue seeks to develop therapeutics that not only improve patient outcomes but also empower the immune system to effectively combat various diseases.

The scientific foundation of ImmVue's technology is rooted in the TEC kinase family, particularly the roles of ITK and BTK in T and B cell function. ITK is crucial for T cell activation and migration, while BTK is essential for B cell development and antibody production. ImmVue's research has demonstrated that pharmacological activation of ITK can enhance T cell efficacy and resilience against inhibitory signals, while BTK agonism can improve plasma cell generation. These insights have led to the development of a novel allosteric approach to modulate intracellular kinases, enabling T and B lymphocytes to better identify and eliminate abnormal or infected cells, including tumors.

Canada

ImmVue Therapeutics is a company that develops small-molecule screen KISMEHT to identify allosteric modulators of the kinase family. Its lead compounds use lymphocytes and aim to revert patients to their vibrant selves with innovative medicines that target novel mechanisms to revitalize their immune system.

ImmVue Therapeutics

Company Details